Neuronal loss occurs with aging or dementia, and an extended concept of neuroprotection assumes that the administration of a drug, or a procedure, is able to reverse or prevent neuronal damage. Neuroprotective strategies have been classified according to the mechanisms of neuronal death, and this chapter will deal mainly with neuroinflammation and related processes that occur in aging, cognitive decline, and dementia. The evidence for inflammatory phenomena in dementia, especially in Alzheimer’s disease (AD), is impressive, and the role of inflammatory cells and mediators has been extensively studied. Furthermore, anti-inflammatory drugs (specially the nonsteroidal anti-inflammatory drugs (NSAIDs)) have been shown to attenuate these phenomena in preclinical studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
11. References
Aisen, P.S., 2002, The potential of anti-inflammatory drugs for the treatment of Alzheimer’s disease. The Lancet Neurology 1: 279.
Aisen, P.S., Davis, K.L., Berg, J.D., Schafer, K., Campbell, K., Thomas, R.G., Weiner, M.F., Farlow, M.R., Sano, M., Grundman, M. and Thal, L.J., 2000, A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology 54: 588.
Aisen, P.S., Schmeidler, J., Pasinetti, G.M., 2002, Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology 58: 1050.
Aisen, P.S., Schafer, K.A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K.L., Farlow, M.R., Jin, S., Thomas, R.G. and Thal, L.J., 2003, Alzheimer’s Disease Cooperative Study. Effects of rofecoxib or naproxen vs. placebo on Alzheimer’s disease progression: a randomized controlled trial. JAMA 289: 2819.
Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., Fiebich, B.L., Finch, C.E., Frautschy, S., Griffin, W.S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I.R., McGeer, P.L., O’Banion, M.K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F.L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G. and Wyss-Coray, T., 2000, Inflammation and Alzheimer’s disease. Neurobiol. Aging 21: 383.
Akwa, Y., Allain, H., Bentue-Ferrer, D., Berr, C., Bordet, R., Geerts, H., Nieoullon, A., Onteniente, B. and Vercelletto, M., 2005, Neuroprotection and neurodegenerative diseases: from biology to clinical practice. Alzheimer Dis. Assoc. Disord. 19: 226.
Alarcon, R., Fuenzalida, C., Santibanez, M. and von Bernhardi, R., 2005, Expression of scavenger receptors in glial cells. Comparing the adhesion of astrocytes and microglia from neonatal rats to surface-bound beta-amyloid. J. Biol. Chem. 280: 30406.
American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders, 4th edition. American Psychiatric Association, Washington.
Andersen, K., Launer, L.J., Ott, A., Hoes, A.W., Breteler, M.M. and Hofman, A., 1995, Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology 45: 1441.
Anthony, J.C., Breitner, J.C., Zandi, P.P., Meyer, M.R., Jurasova, I., Norton, M.C. and Stone, S.V., 2000, Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54: 2066.
Bauer, J., Konig, G., Strauss, S., Jonas, U., Ganter, U., Weidemann, A., Monning, U., Masters, C.L., Volk, B., Berger, M., et al., 1991, In vitro matured human macrophages express Alzheimer’s beta A4-amyloid precursor protein indicating synthesis in microglial cells. FEBS Lett. 282: 335.
Beard, C.M., Waring, S.C., O’Brien, P.C., Kurland, L.T. and Kokmen, E., 1998, Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin. Proc. 73: 951.
Bennett, D.A., Wilson, R.S., Schneider, J.A., Evans, D.A., Beckett, L.A., Aggarwal, N.T., Barnes, L.L., Fox, J.H. and Bach, J., 2002, Natural history of mild cognitive impairment in older persons. Neurology 59: 198.
Bitting, L., Naidu, A., Cordell, B. and Murphy, G.M. Jr., 1996, Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide. J. Biol. Chem. 271: 16084
Bodick, N., Forette, F., Hadler, D., Harvey, R.J., Leber, P., McKeith, I.G., Riekkinen, P.J., Rossor, M.N., Scheltens, P., Shimohama, S., Spiegel, R., Tanaka, S., Thal, L.J., Urata, Y., Whitehouse, P. and Wilcock, G., 1997, Protocols to demonstrate slowing of Alzheimer’s disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. Alzheimer Dis. Assoc. Disord. 11: 50.
Bour, A.M., Westendorp, R.G., Laterveer, J.C., Bollen, E.L. and Remarque, E.J., 2000, Interaction of indomethacin with cytokine production in whole blood. Potential mechanism for a brain-protective effect. Exp. Gerontol. 35: 1017.
Bradt, B.M., Kolb, W.P. and Cooper, N.R., 1998, Complement dependent proinflammatory properties of the Alzheimer’s disease beta-peptide. J. Exp. Med. 188: 431.
Breitner, J.C., Gau, B.A., Welsh, K.A., Plassman, B.L., McDonald, W.M., Helms, M.J. and Anthony, J.C., 1994, Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 44: 227.
Breitner, J.C., Welsh, K.A., Helms, M.J., Gaskell, P.C., Gau, B.A., Roses, A.D, Pericak-Vance, M.A. and Saunders, A.M., 1995, Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol. Aging 16: 523.
Broe, G.A., Henderson, A.S., Creasey, H., McCusker, E., Korten, A.E., Jorm, A.F., Longley, W. and Anthony, J.C., 1990, A case-control study of Alzheimer’s disease in Australia. Neurology 40: 1698.
Butterfield, D.A., Drake, J., Pocernich, C. and Castegna, A., 2001, Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7: 548.
Cohen, O., Zylber-Katz, E., Caraco, Y., Granit, L. and Levy, M., 1998, Cerebrospinal fluid and plasma concentrations of dipyrone metabolites after a single oral dose of dipyrone. Eur. J. Clin. Pharmacol. 54: 549.
Colton, C.A., Chernyshev, O.N., Gilbert, D.L. and Vitek, M.P., 2000, Microglial contribution to oxidative stress in Alzheimer’s disease. Ann. NY Acad. Sci. 899: 292.
Combs, C.K., Johnson, D.E., Cannady, S.B., Lehman, T.M. and Landreth, G.E., 1999, Identification of microglial signal pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J. Neurosci. 19: 928.
Combs, C.K., Johnson, D.E., Karlo, J.C., Cannady, S.B. and Landreth, G.E., 2000, Inflammatory mechanisms in Alzheimer’s disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20: 558.
Cornelius, C., Fratiglioni, L., Fastbom, J., Guo, Z., Viitanem, M. and Winblad, B., 1998, No support for a protective role of NSAIDS against Alzheimer’s disease - a follow-up population-based study. Neurobiol. Aging 19: 28.
Cornelius, C., Fastbom, J., Winblad, B. and Viitanen, M., 2004, Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology 23: 135.
Cotman, C.W., Tenner, A.J. and Cummings, B.J., 1996, Beta-amyloid converts an acute phase injury response to chronic injury responses. Neurobiol. Aging 17: 723.
Davis, J.B., McMurray, H.F. and Schubert, D., 1992, The amyloid Beta-protein of Alzheimer’s disease is chemotactic for mononuclear phagocytes. Biochem. Biophys. Res. Commun. 189: 1096.
de Castro, M., Mota-Filipe, H., Caneira, M., Rico, J.M., Scott-Burden, T. and Vanhoutte, P.M., 1994, DL-propranolol augments production of NO induced by cytokines in cultured aortic smooth muscle of the rat. Eur. J. Pharmacol. 261: 199.
de Mendonça, A., Sebastião, A.M. and Ribeiro, J.A., 2000, Adenosine: does it have a neuroprotective role after all? Brain Res. Rev. 33: 258.
de Mendonça, A., Guerreiro, M., Ribeiro, F., Mendes, T. and Garcia, C., 2004, Mild cognitive impairment: focus on the diagnosis. J. Mol. Neurosci. 23: 13.
Delis, D.C., Kramer, J.H., Kaplan, E. and Ober, B.A., 1987, California Verbal Learning Test: Adult Version Manual. The Psychological Corporation, San Antonio, Texas.
Dembo, G., Park, S.B. and Kharasch, E.D., 2005, Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology 102: 409.
DeWitt, D.A., Perry, G., Cohen, M., Doller, C. and Silver, J., 1998, Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer’s disease. Exp. Neurol. 149: 329.
Dickson, D.W., 1997, The pathogenesis of senile plaques. J. Neuropathol. Exp. Neurol. 56: 321.
Dickson, D.W., Lee, S.C., Mattiace, L.A., Yen, S.H. and Brosnan, C., 1993, Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer’s disease. Glia 7: 75.
Eikelenboom, P., Veerhuis, R., 1996, The role of complement and activated microglia in the pathogenesis of Alzheimer’s disease. Neurobiol. Aging 17: 673.
El Khoury, J., Hickman, S.E., Thomas, C.A., Cao, L., Silverstein, S.C. and Loike, J.D., 1996, Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature 382: 716.
El Khoury, J., Hickman, S.E., Thomas, C.A., Loike, J.D. and Silverstein, S.C., 1998, Microglia, scavenger receptors, and the pathogenesis of Alzheimer’s disease. Neurobiol. Aging 19: S81.
Endoh, M., Kunishita, T. and Tabira, T., 1999, No effect of anti-leprosy drugs in the prevention of Alzheimer’s disease and beta-amyloid neurotoxicity. J. Neurol. Sci. 165: 28.
Eriksen, J.L., Sagi, S.A., Smith, T.E., Weggen, S., Das, P., McLendon, D.C., Ozols, V.V., Jessing, K.W., Zavitz, K.H., Koo, E.H. and Golde, T.E., 2003, NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112: 440.
Etminan, M., Gill, S. and Samii, A., 2003, Effect of nonsteroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ 327: 128.
Farrell, M.J., Katz, B. and Helme, R.D., 1996, The impact of dementia on the pain experience. Pain 67: 7.
FitzGerald, G.A. and Patrono, C., 2001, The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345: 433.
Fourrier, A., Letenneur, L., Begaud, B. and Dartigues, J.F., 1996, Nonsteroidal antiinflammatory drug use and cognitive function in the elderly: inconclusive results from a population-based cohort study. J. Clin. Epidemiol. 49: 1201.
French, L.R., Schuman, L.M., Mortimer, J.A., Hutton, J.T., Boatman, R.A. and Christians, B., 1985, A case-control study of dementia of the Alzheimer type. Am. J. Epidemiol. 121: 414.
Friedman, W.J., 2001, Cytokines regulate expression of the type 1 interleukin-1 receptor in rat hippocampal neurons and glia. Exp. Neurol. 68: 23.
Garcia, C., 1984, A doença de Alzheimer. Problemas de diagnóstico clínico (Alzheimer’s disease. Difficulties of clinical diagnosis), Ph.D. Thesis, Universidade de Lisboa.
Gauthier, S., Touchon, J., 2005, Mild cognitive impairment is not a clinical entity and should not be treated. Arch. Neurol. 6: 1164.
Gewurz, H., Ying, S-C., Jiang, H. and Lint, T.E., 1993, Nonimmune activation of the classical complement pathway. Behring. Inst. Mitt. 93: 138.
Giulian, D., 1999, Microglia and the immune pathology of Alzheimer’s disease. Am. J. Hum. Genet. 65: 13.
Giulian, D., Haverkamp, L.J., Yu, J.H., Karshin, W., Tom, D., Li, J., Kirkpatrick, J., Kuo, L.M. and Roher, A.E., 1996, Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J. Neurosci. 16: 6021.
Gómez-Isla, T., Price, J.L., McKeel, D.W., Jr., Morris, J.C., Growdon, J.H. and Hyman, B.T., 1996, Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J. Neurosci. 16: 4491.
Gómez-Isla, T., Muñoz, G., Ferro, J.M., Lage, J.M.M. and Ramírez, J.C.N., 2006, A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment. Alzheimers Dement 2: S512.
Goodwin, J.L., Uemura, E. and Cunnick, J.E., 1995, Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma. Brain Res. 692: 207.
Gordon, M.L., Mirza, N., Bauer, L., Spoor, E., Overman, G., Dustin, I., Fleischer, T.A., Putman, K., Cohen, R.M. and Sunderland, T., 2006, Intravenous pulse cyclophosphamide in Alzheimer’s disease: results of a pilot dose-finding study. Alzheimers Dement 2: S360.
Graves, A.B., White, E., Koepsell, T.D., Reifler, B.V., van Belle, G., Larson, E.B. and Raskind, M., 1990, A case- control study of Alzheimer’s disease. Ann. Neurol. 28: 766.
Griffin, W.S., 2006, Inflammation and neurodegenerative diseases. Am. J. Clin. Nutr. 83: 470.
Griffin, W.S., Sheng, J.G., Roberts, G.W. and Mrak, R.E., 1995, Interleukin-1 expression in different plaque types in Alzheimer’s disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 54: 276.
Guerreiro, M., 1998, Contributo da Neuropsicologia para o Estudo das Demências (Contribution of neuropsychology to the study of dementia), Ph.D. Thesis, Universidade de Lisboa.
Halliday, G., Robinson, S.R., Shepherd, C. and Kril, J., 2000, Alzheimer’s disease and inflammation: a review of cellular and therapeutic mechanisms. Clin. Exp. Pharmacol. Physiol. 27: 1.
Hamilton, M., 1960, A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23: 56.
Hayden, K.M., Zandi, P.P., Khachaturian, A.S., Pieper, C.F., Sanders, L., Ostbye, T., Tschanz, J.T., Norton, M.C., Munger, R., Lyketsos, C.G., Breitner, J.C.S. and Welsh-Bohmer, K.A., 2006, Modification of cognitive trajectories: NSAID use in the Cache County Study. Alzheimers Dement 2:S174.
Henderson, A.S., Jorm, A.F., Korten, A.E., Creasey, H., McCusker, E., Broe, G.A., Longley, W. and Anthony, J.C., 1992, Environmental risk factors for Alzheimer’s disease: their relationship to age of onset and to familial or sporadic types. Psychol. Med. 22: 429.
Henderson, A.S., Jorm, A.F., Christensen, H., Jacomb, P.A. and Korten, A.E., 1997, Aspirin, anti-inflammatory drugs and risk of dementia. Int. J. Geriatr. Psychiatry 12: 926.
Heneka, M.T., Klockgether, T. and Feinstein, D.L., 2000, Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 20: 6862.
Hewett, S.J., Uliasz, T.F., Vidwans, A.S. and Hewett, J.A., 2000, Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J. Pharmacol. Exp. Ther. 293: 417.
Heyman, A., Wilkinson, W.E., Stafford, J.A., Helms, M.J., Sigmon, A.H. and Weinberg, T., 1984, Alzheimer’s disease: a study of epidemiological aspects. Ann. Neurol. 15: 335.
Ho, L., Pieroni, C., Winger, D., Purohit, D.P., Aisen, P.S. and Pasinetti, G.M.J., 1999, Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer’s disease. Neurosci. Res. 57: 295.
Hüll, M., Lieb, K. and Fiebich, B.L., 2002, Pathways of inflammatory activation in Alzheimer’s disease: potential targets for disease modifying drugs. Curr. Med. Chem. 9: 83.
Hurley, S.D., Walter, A.S., Semple-Rowland, S.L. and Streit, W.J., 1999, Cytokine transcripts expressed by microglia in vitro are not expressed by ameboid microglia at the developing rat central nervous system. Glia 25: 304.
Imbimbo, B.P., 2004, The potential role of nonsteroidal anti-inflammatory drugs in treating Alzheimer’s disease. Expert. Opin. Investig. Drugs 13: 1469.
International Classification of Disease. Word Health Organization, 1992, The ICD-10 Classification of Mental and Behavioral Disorders. World Health Organization, Geneva, Switzerland.
in’t Veld, B.A., Launer, L.J., Hoes, A.W., Ott, A., Hofman, A., Breteler, M.M. and Stricker, B.H., 1998, NSAIDs and incident Alzheimer’s disease. The Rotterdam Study. Neurobiol. Aging 19: 607.
in’t Veld, B.A., Launer, L.J., Breteler, M.M., Hofman, A. and Stricker, B.H., 2002, Pharmacologic agents associated with a preventive effect on Alzheimer’s disease: a review of the epidemiologic evidence. Epidemiol. Rev. 24: 248.
Ishizuka, K., Kimura, T., Igata-yi, R., Katsuragi, S., Takamatsu, J. and Miyakawa, T., 1997, Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psychiatry Clin. Neurosci. 51: 135.
Jelic, V., Kivipelto, M. and Winblad, B., 2005, Clinical trials in mild cognitive impairment: lessons for the future. J Neurol. Neurosurg. Psychiatry, Published on-line, 23 Nov 2005.
Jenkinson, M.L., Bliss, M.R., Brain, A.T. and Scott, D.L., 1989, Rheumatoid arthritis and senile dementia of the Alzheimer’s type. Br. J. Rheumatol. 28: 86.
Johnstone, M., Gearing, A.J. and Miller, K.M., 1999, A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J. Neuroimmunol. 93: 182.
Kanowski, S. and Hoerr, R., 2003, G. biloba extract Egb 761 in dementia intent-to-treat analysis of a 24-week, multi-center, double-blind, placebo controlled, randomized trial. Pharmacopsychiatry 63: 297.
Kelley, K.A., Ho, L., Winger, D., Freire-Moar, J., Borelli, C.B., Aisen, P.S. and Pasinetti, G.M., 1999, Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am. J. Pathol. 155: 995.
Kitamura, Y., Shimohama, S., Koike, H., Kakimura, J., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P.J. and Taniguchi, T., 1999, Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer’s disease brains. Biochem. Biophys. Res. Commun. 254: 582.
Kittner, B., Rossner, M. and Rother, M., 1997, Clinical trials in dementia with propentofylline. Ann. NY Acad. Sci. 826: 307.
Klegeris, A. and McGeer, P.L., 1997, Beta-amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J. Neurosci. Res. 49: 229.
Knopman, D., Kahn, J. and Miles, S., 1998, Clinical Research Designs for Emerging Treatments for Alzheimer’s disease. Arch. Neurol. 55: 1425.
Kopec, K.K. and Carroll, R.T., 1998, Alzheimer’s beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia. J. Neurochem. 71: 2123.
Kunz, T. and Oliw, E.H., 2001, The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur. J. Neurosci. 13: 569.
Lawton, M.P. and Brody, E.M., 1969, Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9: 179.
Lee, Y.B., Nagai, A. and Kim, S.U., 2002, Cytokines, chemokines, and cytokine receptors in human microglia. J. Neurosci. Res. 69: 94.
Leszek, J. and Gasiorowski, K., 1996, Therapeutic efficay of cyclophosphamide in Alzheimer’s disease. Alzheimers Res. 2: 43.
Levi, M.S. and Brimble, M.A., 2004, A review of neuroprotective agents. Curr. Med. Chem. 11: 2383.
Lue, L.F., Yan, S.D. and Stern, D.M., 2005, Preventing activation of receptor for advanced glycation endproducts in Alzheimer’s disease. Curr. Drug Targets CNS Neurol. Disord. 4: 249.
Lukiw, W.J. and Bazan, N.G., 1997, Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J. Neurosci. Res. 50: 937.
McDonald, D.R., Brunden, K.R. and Landreth, G.E., 1997, Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J. Neurosci. 17: 2284.
McDonald, D.R., Bamberger, M.E., Combs, C.K. and Landreth, G.E., 1998, Abeta-amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J. Neurosci. 18: 4451.
McGeer, P.L., Schulzer, M. and McGeer, E.G., 1996, Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology 47: 425.
McGeer, E.G., Yasojima, K., Schwab, C. and McGeer, P.L., 2001, The pentraxins: possible role in Alzheimer’s disease and other innate inflammatory diseases. Neurobiol. Aging 22: 843.
Meda, L., Cassatella, M.A., Szendrei, G.I., Otvos, L., Jr., Baron, P., Villalba, M., Ferrari, D. and Rossi, F., 1995, Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 374: 647.
Meda, L., Baron, P. and Scarlato, G., 2001, Glial activation in Alzheimer’s disease: the role of Abeta and its associated proteins. Neurobiol. Aging 22: 885.
Mendes, T., 2003, Memory and Metamemory: from the young to the aged. Master degree thesis, Faculdade de Medicina da Universidade de Lisboa.
Moreira, P.I., Honda, K., Liu, Q., Santos, M.S., Oliveira, C.R., Aliev, G., Nunomura, A., Zhu, X., Smith, M.A. and Perry, G., 2005, Oxidative stress: the old enemy in Alzheimer’s disease pathophysiology. Curr. Alzheimer Res. 2: 403.
Mrak, R.E. and Griffin, W.S., 2001, Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol. Aging 22: 903.
Nakayama, M., Uchimura, K., Zhu, R.L., Nagayama, T., Rose, M.E., Stetler, R.A., Isakson, P.C., Chen, J. and Graham, S.H., 1998, Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc. Natl. Acad. Sci. USA. 95: 10954.
Ogawa, O., Umegaki, H., Sumi, D., Hayashi, T., Nakamura, A., Thakur, N.K., Yoshimura, J., Endo, H. and Iguchi, A., 2000, Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in betaamyloid protein-stimulated J774 cells. Eur. J. Pharmacol. 408: 137.
Pasinetti, G.M. and Aisen, P.S., 1998, Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain. Neuroscience 87: 319.
Perry, R.T., Collins, J.S., Wiener, H., Acton, R. and Go, R.C., 2001, The role of TNF and its receptors in Alzheimer’s disease. Neurobiol. Aging 22: 873.
Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G. and Kokmen, E., 1999, Mild cognitive impairment. Arch. Neurol. 56: 303.
Petersen, R.C., Doody, R., Kurz, A., Mohs, R.C., Morris, J.C., Rabins, P.V., Ritchie, K., Rossor, M., Thal, L. and Winblad, B., 2001a, Current concepts in mild cognitive impairment. Arch. Neurol. 58: 1985.
Petersen, R.C., Stevens, J.C., Ganguli, M., Tangalos, E.G., Cummings, J.L. and DeKosky, S.T., 2001b, Practice parameter: early detection of dementia, mild cognitive impairment (an evidence-based review). Neurology 56: 1133.
Petersen, R.C., Thomas, R.G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., Pfeiffer, E., Sano, M., van Dyck, C.H. and Thal, L.J.; Alzheimer’s Disease Cooperative Study Group, 2005, Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352: 2379.
Raskind, M.A., Peskind, E.R., Truyen, L., Kershaw, P. and Damaraju, C.V., 2004, The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch. Neurol. 61: 252.
eines, S.A., Block, G.A., Morris, J.C., Liu, G., Nessly, M.L., Lines, C.R., Norman, B.A. and Baranak, C.C., 2004, Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66.
Ribeiro, F., de Mendonça, A. and Guerreiro, M., 2006, Mild Cognitive Impairment: deficits in cognitive domains other than memory. Dement. Geriatr. Cogn. Disord. 21: 284.
Ribeiro, F., Guerreiro, M. and de Mendonça, A., 2007, Verbal learning and memory deficits in Mild Cognitive Impairment. J. Clin. Exp. Neuropsychol. 29: 187.
Ritchie, K., Artero, S. and Touchon, J., 2001, Classification criteria for mild cognitive impairment - A population-based validation study. Neurology 56: 37.
Robertson, M., 2003, Effect of NSAIDs on risk of Alzheimer’s disease: confounding factors were not discussed. BMJ 327: 751.
Rogers, J., Luber-Narod, J., Styren, S.D. and Civin, W.H., 1988, Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol. Aging 9: 339.
Rogers, J., Cooper, N.R., Webster, S. et al., 1992, Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 89: 10016.
Rogers, J., Kirby, L.C., Hempelman, S.R., Berry, D.L., McGeer, P.L., Kaszniak, A.W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P. et al., 1993, Clinical trial of indomethacin in Alzheimer’s disease. Neurology 43: 1609.
Rother, M., Erkinjuntti, T., Roessner, M., Kittner, B., Marcusson, J. and Karlsson, I., 1998, Propentofylline in the treatment of Alzheimer’s disease and vascular dementia: a review of phase III trials. Dement. Geriatr. Cogn. Disord. 9 S1: 36.
Rudolphi, K.A., Park, C.K. and Rother, M., 1997, Propentofylline(HWA 285), a neuroprotective glial cell modulator: pharmacologic profile. CNS Drug. Rev. 3: 260.
Sano, M., Ernesto, C., Thomas, R.G., Klauber, M.R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., Schneider, L.S. and Thal, L.J., 1997, A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N. Engl. J. Med. 336: 1216.
Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., Evert, B.O., Dumitrescu-Ozimek, L., Thal, D.R., Landreth, G., Walter, J., Klockgether, T., van Leuven, F. and Heneka, M.T., 2006, Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. USA 103: 443.
Scharf, S., Mander, A., Ugoni, A., Vajda, F. and Christophidis, N., 1999, A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 53: 197.
Schimmer, B., and Parker, K.L., 2006, Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. L.L. Brunton (ed.). McGraw Hill, NY, pp. 653-670.
Schmand, B., Jonker, C., Hooijer, C. and Lindeboom, J., 1996, Subjective memory and memory complaints may announce dementia. Neurology 46: 121.
Schmidt, L.A., Fox, A., Goldberg, M.C., Smith, C.C. and Schulkin, J., 1999, Effects of acute prednisone administration on memory, attention, and emotion in healthy human adults. Psychoneuroendocrinology 24: 461.
Schneider, L.S., DeKosky, S.T., Farlow, M.R., Tariot, P.N., Hoerr, R. and Kieser, M., 2005, A randomized, double-blind, placebo control trial of two doses of G. biloba extract in dementia of Alzheimer’s type. Curr. Alzheimer Res. 2: 495.
Shaffer, L.M., Dority, M.D., Gupta-Bansal, R., Frederickson, R.C., Younkin, S.G. and Brunden, K.R., 1995, Amyloid beta protein (A beta) removal by neuroglial cells in culture. Neurobiol. Aging 16: 737.
Shen, Y. and Meri, S., 2003, Yin and Yang: complement activation and regulation in Alzheimer’s disease. Prog. Neurobiol. 70: 463.
Shen, Y., Li, R., McGeer, E.G. and McGeer, P.L., 1997, Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 769: 391.
Shen, Y., Lue, L., Yang, L., Roher, A., Kuo, Y., Strohmeyer, R., et al., 2001, Complement activation by neurofibrillary tangles in Alzheimer’s disease. Neurosci. Lett. 305: 165.
Shirahama, T., Miura, K., Ju, S.T., Kisilevsky, R., Gruys, E. and Cohen, A.S., 1990, Amyloid enhancing factor-loaded macrophages in amyloid fibril formation. Lab. Invest. 62: 61.
Smits, H.A., Rijsmus, A., van Loon, J.H., Wat, J.W., Verhoef, J., Boven, L.A. and Nottet, H.S., 2002, Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J. Neuroimmunol. 127: 160.
Smyth, E.M., Burke, A. and FitzGerald, G.A., 2006, Lipid-derived autacoids: eisosanoids and platett activating factor. In: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. L.L. Brunton, (ed.). McGraw Hill, NY, pp. 653-670.
Stern, R.G., Mohs, R.C., Davidson, M., Schmeidler, J., Silverman, J., Kramer-Ginsberg, E., Searcey, T., Bierer, L. and Davis, K.L., 1994, A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am. J. Psychiatry 151: 390.
Stewart, W.F., Kawas, C., Corrada, M. and Metter, E.J., 1997, Risk of Alzheimer’s disease and duration of NSAID use. Neurology 48: 626.
Streit, W.J., Walter, S.A., Permell, N.A., 1999, Reactive microgliosis. Prog. Neurobiol. 57: 563.
Strohmeyer, R., Shen, Y. and Rogers, J., 2000, Detection of complement alternative pathway mRNA and proteins in the Alzheimer’s disease brain. Brain Res. Mol. Brain Res. 81: 7.
Stuchbury, G. and Munch, G., 2005, Alzheimer’s associated inflammation, potential drug targets and future therapies. J. Neural Transm. 112: 429.
Styren, D.S., Civin, W.H. and Rodgers, J., 1990, Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer’s disese brain. Exp. Neurol. 110: 93.
Suzuki, S., Tanaka, K., Nagata, E., Ito, D., Dembo, T. and Fukuuchi, Y., 1999, Cerebral neurons express interleukin-6 after transient forebrain ischemia in gerbils. Neurosci. Lett. 262: 117.
Szekely, C.A., Thorne, J.E., Zandi, P.P., Ek, M., Messias, E., Breitner, J.C. and Goodman, S.N., 2004, Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review. Neuroepidemiology 23: 159.
Tabet, N. and Feldman, H., 2002, Indomethacin for the treatment of Alzheimer’s disease patients. Cochrane Database Syst. Rev. 2: CD003673.
Tabet, N. and Feldman, H., 2003, Ibuprofen for Alzheimer’s disease. Cochrane Database Syst Rev. 2:CD004031.
Tarkowski, E., Liljeroth, A.M., Minthon, L., Tarkowski, A., Wallin, A. and Blennow, K., 2003, Cerebral pattern of cytokines in dementias. Brain Research Bulletin 61: 255.
Taylor, D., Paton, C. and Kerwin, R., 2005, Use of psychotropics in special patient groups. The Maudseley 2005-2006 Prescribing Guidelines, 8th edition. Taylor and Francis, London and New York, pp. 259-335.
Tchelingerian, J.L., Vignais, L. and Jacque, C., 1994, TNF alpha gene expression is induced in neurones after a hippocampal lesion. Neuroreport 5: 585.
Terai, K., Walker, D.G., McGeer, M.G. and McGeer, P.L., 1997, Neurons express proteins of the classic complement pathway in Alzheimer’s disease. Brain Res. 769: 385.
Thal, L.J., Grundman, M., Berg, J., Ernstrom, K., Margolin, R., Pfeiffer, E., Weiner, M.F., Zamrini, E. and Thomas, R.G., 2003, Idebenone fails to slow cognitive decline in Alzheimer’s disease. Neurology 61: 1498.
Thal, L.J., Ferris, S.H., Kirby, L., Block, G.A., Lines, C.R., Yuen, E., Assaid, C., Nessly, M.L., Norman, B.A., Baranak, C.C. and Reines, S.A., Rofecoxib Protocol 078 study group, 2005, A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30: 1204.
The Canadian Study of Health and Aging, 1994, Risk factors for Alzheimer’s disease in Canada. Neurology 44: 2073.
Tobinick, E.L., Gross, H., Weinberger, A. and Cohen, H., 2006, TNF-alpha modulation for treatment of Alzheimer’s disease: a six month pilot study. Alzheimers Dement 2: S364.
Tuppo, E.E. and Arias, H.R., 2005, The role of inflammation in Alzheimer’s disease. Int. J. Biochem. Cell. Biol. 37: 289.
Van Gool, W.A., Weinstein, H.C., Scheltens, P., Walstra, G.J., 2001, Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 358: 455.
Vane, J. and Botting, R., 1987, Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J. 1: 89.
Visser, P.J., Scheltens, P. and Verhey, F.R., 2005, Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer’s disease? J. Neurol. Neurosurg. Psychiatry 76: 1348.
Watson, G.S., Cholerton, B.A., Reger, M.A., Baker, L.D., Plymate, S.R., Asthana, S., Fishel, M.A., Kulstad, J.J., Green, P.S., Cook, D.G., Kahn, S.E., Keeling, M.L. and Craft, S., 2005, Preserved cognition in patients with early Alzheimer’s disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary, study. Am. J. Geriatr. Psychiatry 13: 950.
Webster, S., Lue, L.F., Brachova, L., Tenner, A.J., McGeer, P.L., Terai, K., Walker, D.G., Bradt, B., Cooper, N.R. and Rogers, J., 1997, Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer’s disease. Neurobiol. Aging 18: 415.
Wechsler, D., 1969, Manuel de l’Échelle Clinique de Mémoire. Centre de Psychologie Appliquée, Paris.
Weggen, S., Eriksen, J.L., Das, P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., Smith, T.E., Murphy, M.P., Bulter, T., Kang, D.E., Marquez-Sterling, N., Golde, T.E. and Koo, E.H., 2001, A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212.
Weggen, S., Eriksen, J.L., Sagi, S.A., Pietrzik, C.U., Ozols, V., Fauq, A., Golde, T.E. and Koo, E.H., 2003, Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J. Biol. Chem. 278: 31831.
Whitehouse, P.J., Kittner, B., Roessner, M., Rossor, M., Sano, M., Thal, L. and Winblad, B., 1998, Clinical trial designs for demonstrating disease-course-altering effects in dementia. Alzheimer Dis. Assoc. Disord. 12: 281.
Wilson, C.J., Finch, C.E. and Cohen, H.J., 2002, Cytokines and cognition - the case for a head-to-toe inflammation paradigm. J. Am. Geriat. Soc. 50: 2041.
Wolkowitz, O.M., Reus, V.I., Canink, J., Levin, B., Lupien, S., 1997, Glucocorticoid medication, memory and steriod psychosis in medical illness. Ann. NY Acad. Sci. 832: 37.
Yan, S.D., Stern, D., Kane, M.D., Kuo, Y.M., Lampert, H.C. and Roher, A.E., 1998, RAGE-Abeta interactions in the pathophysiology of Alzheimer’s disease. Restor. Neurol. Neurosci. 12: 167.
Yasojima, K., Schwab, C., McGeer, E.G. and McGeer, P.L., 1999a, Up-regulated production and activation of the complement system in Alzheimer’s disease brain. Am. J. Pathol. 154: 927.
Yasojima, K., Schwab, C., McGeer, E.G. and McGeer, P.L., 1999b, Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830: 226
Yasojima, K., Schwab, C., McGeer, E.G. and McGeer, P.L., 2000, Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease. Brain Res. 887: 80.
Yesavage, J.A., Brink, T.L., Rose, T.L., Lum, O., Huang, V., Adey, M. and Leirer, O., 1983, Development and validation of a geriatric depression scale: a preliminary report. J. Psych. Res. 17: 37.
Zandi, P.P. and Breitner, J.C., 2001, Do NSAIDs prevent Alzheimer’s disease? And, if so, why? The epidemiological evidence. Neurobiol. Aging 22: 811.
Zhang, Y., Raud, J., Hedqvist, P. and Fredholm, B.B., 1996, Propentofylline inhibits polymorphonuclear leukocyte recruitment in vivo by a mechanism involving adenosine A2A receptors. Eur. J. Pharmacol. 313: 237.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Couto, F.S.d., Mendonça, A.d. (2007). Aging and Cognitive Decline: Neuroprotective Strategies. In: Malva, J.O., Rego, A.C., Cunha, R.A., Oliveira, C.R. (eds) Interaction Between Neurons and Glia in Aging and Disease. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-70830-0_11
Download citation
DOI: https://doi.org/10.1007/978-0-387-70830-0_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-70829-4
Online ISBN: 978-0-387-70830-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)